ArticleBMC medical informatics and decision making2026
Dynamic Bayesian networks to predict loss of kidney function: a cross-institution use case in a large cohort with or at-risk of CKD.
Article in BMC medical informatics and decision making, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSubstantial loss of kidney function, measured as ≥40% decline in estimated glomerular filtration rate (eGFR) within a 2-year period, is associated with a tenfold increase in the risk for kidney failure.
methodsWe developed and externally validated dynamic Bayesian networks (DBNs) to predict ≥ 40% eGFR decline using electronic health record (EHR) data from Providence and UCLA Health.
resultsOf 2.25 million patients, with and at-risk for chronic kidney disease (CKD), 6.49% (146,043 individuals) experienced at least one occurrence of ≥40% decline from baseline eGFR over six years of follow-up. The DBNs demonstrated strong predictive performance, as measured by the area under the receiver operating characteristic curve (AUCROC) and average precision (AP), with the highest values observed in the final year (Year 6), ranging from 0.83-0.89 and 0.28-0.37, respectively. A comparison of existing gold-standard CKD-Prognosis Consortium risk equations in real-world clinical settings with missing data demonstrated that DBNs' performance remained unaffected, while risk equations performed close to random due to their inability to handle missing data. The temporal structure of the DBNs captured longitudinal features changes and their interactions, with the most important observations over time including the urine albumin-creatinine ratio (UACR), the urine protein-creatinine ratio, and hemoglobin A1c. Notably, comparing DBN performance across institutions revealed that training on larger datasets generalized better.
conclusionThis study offers valuable insights into the development of DBNs using real-world population data from EHRs. The DBNs successfully identified patients at-risk for ≥40% eGFR decline and, despite missing data, offer opportunities for timely intervention and risk mitigation to preserve kidney function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.